Melanoma Survival Rates by Stage: What the Numbers Really Mean

When someone receives a diagnosis of melanoma, the question that almost always comes up first is what this means for survival. The available statistics provide an answer, but understanding what those numbers actually represent requires some context. Survival rates are statistical summaries derived from large populations of patients diagnosed years earlier, and translating these averages into meaning for any specific individual involves understanding both the numbers themselves and what they do not capture.

The good news in melanoma statistics is that, in the great majority of cases diagnosed today, the prognosis is favorable. Most melanomas are diagnosed at early stages, when the cancer is confined to the skin and surgical removal produces excellent outcomes. The five-year survival rate for early-stage melanoma is very high, approaching 100 percent for the earliest stage.

The trajectory of survival in advanced melanoma has changed substantially over the past decade. The introduction of immunotherapy and targeted therapy has transformed what was previously a uniformly devastating diagnosis into a condition with meaningful treatment options and substantially improved survival for many patients. Statistics published a decade ago substantially understate current outcomes for advanced disease.

This article explains how melanoma is staged, what survival rates have been reported for each stage, what the numbers actually mean for individual patients, and how recent treatment advances are changing outcomes.

For more on melanoma broadly, see Melanoma: Early Detection Saves Lives — The "Ugly Duckling" Sign Explained.

What Survival Rates Actually Mean

A five-year survival rate refers to the percentage of patients who are alive five years after diagnosis. The figure does not mean that patients live exactly five years and no longer. Many patients with favorable five-year survival continue to live for decades.

Survival rates are population averages, not individual predictions. A 90 percent five-year survival rate means that, on average, 90 out of 100 patients are alive at five years, but it does not predict any specific individual's outcome.

Survival rates are based on patients diagnosed years earlier, with treatments that may differ from current standards. For melanoma specifically, the rapid evolution of treatment over the past decade means that recently diagnosed patients receive substantially different care than the historical cohorts on which published rates are based.

Several specific measures are commonly reported:

• Overall survival: the percentage alive at a given time point regardless of cause of death
• Disease-specific survival: the percentage who have not died of the cancer specifically
• Disease-free survival: the percentage alive without recurrence

How Melanoma Is Staged

Melanoma staging classifies the cancer based on how advanced it is. The current staging system, developed by the American Joint Committee on Cancer (AJCC), uses the TNM classification.

T (tumor) describes the primary tumor, including its thickness in millimeters (Breslow thickness), whether the surface is ulcerated, and other features.

N (nodes) describes whether the cancer has spread to regional lymph nodes, how many nodes are involved, and whether involvement is microscopic or clinically apparent.

M (metastasis) describes whether the cancer has spread to distant sites beyond the regional lymph nodes.

Stage 0 (Melanoma in Situ)

Stage 0 refers to cancer confined to the outermost layer of the skin (the epidermis). The cancer cells are present but have not yet acquired the ability to spread.

Stage 1

Stage 1 describes localized tumors that are relatively thin and have not spread beyond the skin. It is further divided into Stage 1A and Stage 1B based on tumor thickness and other features.

Stage 2

Stage 2 describes localized tumors that are thicker or have additional concerning features but have not spread to lymph nodes or distant sites. It is divided into Stage 2A, 2B, and 2C based on increasing thickness and presence of ulceration.

Stage 3

Stage 3 describes cancer that has spread to regional lymph nodes or has produced nearby skin metastases. It is divided into multiple substages based on the extent of nodal involvement.

Stage 4

Stage 4 describes cancer that has spread to distant sites beyond the regional lymph nodes. Common sites include the lungs, liver, bones, and brain.

For more on staging and diagnosis, see How Is Melanoma Diagnosed? Skin Examination, Dermoscopy, and Biopsy.

Survival Rates by Stage

Stage 0

Stage 0 melanoma has a five-year survival rate approaching 100 percent. Surgical removal with appropriate margins is generally curative, and recurrence is uncommon when the cancer is removed completely.

Stage 1

Stage 1 melanoma has a five-year survival rate of approximately 95 to 99 percent. Treatment typically involves wide local excision of the primary tumor with appropriate margins. Most patients are cured with surgical treatment alone.

Stage 2

Stage 2 melanoma has more variable survival rates depending on the specific substage:

• Stage 2A: approximately 85 to 95 percent five-year survival
• Stage 2B: approximately 75 to 85 percent
• Stage 2C: approximately 60 to 75 percent

Some patients with Stage 2 melanoma now receive adjuvant therapy after surgery to reduce the risk of recurrence.

Stage 3

Stage 3 melanoma represents a substantial change in prognosis. Five-year survival rates vary widely within Stage 3:

• Stage 3A: approximately 70 to 85 percent
• Stage 3B: approximately 50 to 70 percent
• Stage 3C: approximately 40 to 60 percent
• Stage 3D: approximately 20 to 40 percent (in older data)

The major change for Stage 3 melanoma in recent years has been the introduction of effective adjuvant therapy. Immunotherapy and targeted therapy administered after surgical removal have substantially reduced recurrence rates and improved survival. Current outcomes with modern adjuvant therapy exceed what historical statistics suggest.

Stage 4

Stage 4 melanoma has historically had the most challenging prognosis, with five-year survival rates of 15 to 20 percent in registry data from before the modern era of immunotherapy.

The introduction of immunotherapy and targeted therapy has transformed Stage 4 melanoma substantially. Current data with modern treatments show that approximately 50 percent or more of patients respond to immunotherapy, and a substantial proportion of responders have durable responses persisting for years. Five-year survival rates in clinical trials of modern combination immunotherapy have reached approximately 50 percent or higher in selected populations.

For patients newly diagnosed with Stage 4 melanoma, the prognostic conversation is fundamentally different than it would have been in 2010.

For more on treatment options, see Melanoma Treatment Options: A Complete Guide.

Why Stage Matters So Much

The dramatic difference in survival across stages reflects the underlying biology of cancer progression. Melanoma confined to the skin is a fundamentally different biological situation from melanoma that has spread to lymph nodes or distant sites.

In early-stage disease, the cancer is localized to sites that can be surgically removed. In advanced disease, the cancer has demonstrated the capacity to spread and survive in new locations, requiring systemic treatment rather than local removal.

This is why early detection through skin examination, dermoscopy, and patient education is so important. The difference in outcomes between Stage 1 (five-year survival approaching 99 percent) and Stage 4 (historically much lower) is not marginal but profound.

For more on early detection, see Early Signs of Melanoma: The ABCDE Rule Explained and When Should You Worry About a Mole? Warning Signs Explained.

Factors That Affect Survival Within a Stage

Tumor Thickness (Breslow Depth)

Thinner tumors generally have better outcomes than thicker tumors, even within the same stage.

Ulceration

Ulceration of the primary tumor is associated with worse prognosis. Ulcerated tumors are more aggressive than non-ulcerated tumors of similar thickness.

Mitotic Rate

Higher mitotic rates indicate more rapidly growing tumors and are generally associated with worse outcomes.

Lymph Node Involvement

For Stage 3 melanoma, the number of lymph nodes involved and whether involvement is microscopic or clinically apparent affect prognosis.

BRAF Mutation Status

Approximately half of melanomas carry mutations in the BRAF gene. The presence of this mutation has prognostic implications and also affects treatment options, since targeted therapies specifically target the BRAF mutation.

Additional Factors

Older age at diagnosis, male sex, and certain primary tumor locations are associated with somewhat worse prognosis on average, though individual outcomes vary substantially.

How Modern Treatment Has Changed Outcomes

Immunotherapy

Checkpoint inhibitors, including drugs targeting PD-1 (pembrolizumab and nivolumab) and CTLA-4 (ipilimumab), have produced unprecedented response rates and durability. Combination therapy produces higher response rates than either alone. Response rates with single-agent PD-1 inhibitors are approximately 40 to 45 percent; combination therapy can produce response rates of 60 percent or higher.

Targeted Therapy

For melanomas with BRAF mutations, targeted therapy with BRAF inhibitors plus MEK inhibitors produces high response rates and meaningful survival improvements. Combinations including dabrafenib plus trametinib and encorafenib plus binimetinib are widely used.

Adjuvant Therapy

For Stage 3 melanoma after surgical removal, adjuvant immunotherapy or targeted therapy reduces recurrence rates by approximately 30 to 50 percent compared to observation. Use of adjuvant therapy has expanded to include selected high-risk Stage 2 patients.

Neoadjuvant Therapy

Immunotherapy before surgery (neoadjuvant therapy) for Stage 3 melanoma has shown excellent responses, with substantial improvements in outcomes compared to surgery alone.

For more on treatment, see Melanoma Treatment Options: A Complete Guide and Can Melanoma Be Cured? Understanding the Reality of Treatment and Recovery.

What These Numbers Mean for Individual Patients

For any individual patient, several considerations help translate population statistics into personally meaningful information.

Stage at diagnosis provides the most important single prognostic factor, but it is refined by tumor thickness, ulceration, mitotic rate, lymph node involvement, BRAF status, and patient health. Modern treatment has changed outcomes substantially, particularly for advanced disease. Individual responses vary, with some patients doing substantially better than averages predict. And time matters: many patients with favorable five-year outcomes continue to do well for much longer.

For most patients, conversation with the treating oncologist or dermatologist provides the most relevant prognostic information for their specific situation.

Survivorship and Long-Term Considerations

For patients who survive melanoma, several long-term considerations apply.

• Risk of recurrence is highest in the first few years after diagnosis but declines progressively over time
• Risk of new primary melanomas is approximately 5 to 10 percent over a lifetime, substantially higher than the general population
• Risk of other skin cancers, including basal cell carcinoma and squamous cell carcinoma, is also elevated
• Sun protection becomes a lifelong priority
• Psychological adjustment is part of the long-term picture for many patients

For more, see Sun Exposure and Skin Cancer: What You Need to Know and Who Is at Risk for Melanoma? Understanding the Key Risk Factors.

Why Early Detection Remains Essential

The most powerful way to improve melanoma survival remains early detection. The difference in outcomes between Stage 1 and Stage 4 is dramatic and largely determined by when the cancer is identified.

Regular self-examination, awareness of ABCDE features, attention to the ugly duckling sign, and professional surveillance for higher-risk individuals all contribute to detection at stages where treatment is most effective.

For more on early detection, see Dermoscopy: What Dermatologists Look For When Examining Skin Lesions.

Conclusion

Melanoma survival rates vary dramatically by stage, with excellent outcomes for early-stage disease and progressively reduced outcomes for advanced disease. The five-year survival rate approaches 100 percent for Stage 0, remains very favorable through Stage 1, declines progressively through Stages 2 and 3, and historically has been challenging for Stage 4.

The picture for advanced disease has changed substantially over the past decade. Immunotherapy and targeted therapy have transformed Stage 4 melanoma, with current five-year survival rates in clinical trials reaching approximately 50 percent or higher in selected populations — far exceeding what older statistics would suggest.

For individual patients, stage at diagnosis provides the most important prognostic factor, refined by multiple additional variables. Modern treatment has changed outcomes substantially. The most powerful way to improve outcomes remains early detection, where the difference in survival between early and advanced stages is profound.

For more on the broader context of melanoma, see What Is Melanoma? Symptoms, Causes, and Risk Factors and Melanoma: Early Detection Saves Lives — The "Ugly Duckling" Sign Explained.

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.